《大行報告》美銀證券下調中生製藥(01177.HK)目標價至5.7元 評級「買入」
美銀證券發表報告指,中生製藥(01177.HK)次季總收入按年升30%至86億元人民幣,調整後非香港財務報告準則應佔淨利潤增長20.7%至10億元人民幣;但在上半年期間,公司列賬收入按年升0.5%至153億元人民幣,毛利按年跌1.7%至120億元人民幣,毛利率達78.7%,上半年純利則按年跌34.5%至13億元人民幣。
考慮生物類似藥及仿製藥市場競爭激烈,下調對其2025年起收入預測,目標價由6.7元下調至5.7元;考慮強勁管線發展能力,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.